Literature DB >> 25602162

Cytochrome P450 1A2 co-determines neuroleptic load and may diminish tardive dyskinesia by increased inducibility.

Svetlana A Ivanova1, Valentina A Toshchakova, Maxim L Filipenko, Olga Yu Fedorenko, Evgenia G Boyarko, Anastasia S Boiko, Arkadiy V Semke, Nikolay A Bokhan, Lyubomir I Aftanas, Anton J M Loonen.   

Abstract

OBJECTIVES: The aim of this study was to investigate a possible association between tardive dyskinesia (TD) and CYP1A2 (*1F, -163C>А, rs762551) polymorphism in Russian psychiatric inpatients.
METHODS: TD was assessed cross-sectionally using the Abnormal Involuntary Movement Scale (AIMS). Orofacial and limb-truncal dyskinesia were assessed with AIMS 1-4 and 5-7, respectively. Standard protocols were applied for genotyping. Analysis of covariance (ANCOVA) was used to compare the mean AIMS scores for each of the genotypic classes.
RESULTS: A total of 319 Caucasian patients from West Siberia with schizophrenia and 117 healthy volunteers were investigated. No significant differences between the patients and the controls in genotype frequencies were found. Analysis of covariance (ANCOVA) with age, sex, duration of disease, chlorpromazine equivalent (CPZEQ) incorporated as covariates showed that limb-truncal, but not orofacial TD, is associated with CYP1A2 (-163C>, rs762551) polymorphism (F = 3.27, P = 0.039). Patients with the C/C genotype had a higher mean AIMS 5-7 score than those with the A/C or the A/A genotype.
CONCLUSIONS: Our results support the hypothesis that not only with clozapine, but also with other classical and atypical antipsychotics, smoking may decrease plasma levels; this is most extensively expressed in carriers of the CYP1A2*1F (-163C> A) polymorphism.

Entities:  

Keywords:  CYP1A2 gene; enzyme induction; schizophrenia; tardive dyskinesia; tobacco smoking

Mesh:

Substances:

Year:  2015        PMID: 25602162     DOI: 10.3109/15622975.2014.995222

Source DB:  PubMed          Journal:  World J Biol Psychiatry        ISSN: 1562-2975            Impact factor:   4.132


  5 in total

Review 1.  Pharmacogenetics of Antipsychotic Drug Treatment: Update and Clinical Implications.

Authors:  Kazunari Yoshida; Daniel J Müller
Journal:  Mol Neuropsychiatry       Date:  2018-09-26

2.  Genome wide study of tardive dyskinesia in schizophrenia.

Authors:  Keane Lim; Max Lam; Clement Zai; Jenny Tay; Nina Karlsson; Smita N Deshpande; B K Thelma; Norio Ozaki; Toshiya Inada; Kang Sim; Siow-Ann Chong; Todd Lencz; Jianjun Liu; Jimmy Lee
Journal:  Transl Psychiatry       Date:  2021-06-08       Impact factor: 6.222

Review 3.  Genetic Factors Associated With Tardive Dyskinesia: From Pre-clinical Models to Clinical Studies.

Authors:  Evangelia Eirini Tsermpini; Sara Redenšek; Vita Dolžan
Journal:  Front Pharmacol       Date:  2022-01-24       Impact factor: 5.810

4.  The effect of CYP1A2 gene polymorphism on the metabolism of theophylline.

Authors:  Shijuan Xiong; Lingling Li
Journal:  Exp Ther Med       Date:  2017-10-30       Impact factor: 2.447

5.  Opening up new horizons for psychiatric genetics in the Russian Federation: moving toward a national consortium.

Authors:  Thomas G Schulze; Аleksandr О Kibitov; Olga Yu Fedorenko; Vera E Golimbet; Svetlana А Ivanova; Аnastasia Levchenko; Raul R Gainetdinov; Arkady V Semke; German G Simutkin; Аnna E Gareeva; Аndrey S Glotov; Anna Gryaznova; Ivan Y Iourov; Evgeny M Krupitsky; Igor N Lebedev; Galina E Mazo; Vasily G Kaleda; Lilia I Abramova; Igor V Oleichik; Yulia A Nasykhova; Regina F Nasyrova; Anton E Nikolishin; Evgeny D Kasyanov; Grigory V Rukavishnikov; Ilgiz F Timerbulatov; Vadim M Brodyansky; Svetlana G Vorsanova; Yury B Yurov; Tatyana V Zhilyaeva; Anzhelika V Sergeeva; Elena A Blokhina; Edwin E Zvartau; Anna S Blagonravova; Lyubomir I Aftanas; Nikolay А Bokhan; Zurab I Kekelidze; Tatyana V Klimenko; Irina P Anokhina; Elza K Khusnutdinova; Tatyana P Klyushnik; Nikolay G Neznanov; Vadim A Stepanov
Journal:  Mol Psychiatry       Date:  2019-01-21       Impact factor: 15.992

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.